TY - JOUR
T1 - Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma
AU - Moreau, Philippe
AU - van de Donk, Niels Wcj
AU - Nahi, Hareth
AU - Oriol, Albert
AU - Nooka, Ajay K.
AU - Martin, Thomas
AU - Rosinol, Laura
AU - Karlin, Lionel
AU - Benboubker, Lotfi
AU - Mateos, Maria-Victoria
AU - Popat, Rakesh
AU - Martínez-López, Joaquín
AU - Sidana, Surbhi
AU - Delforge, Michel
AU - Pei, Lixia
AU - Trancucci, Danielle
AU - Olyslager, Yunsi
AU - Uhlar, Clarissa
AU - Stephenson, Tara
AU - Rampelbergh, Rian Van
AU - Banerjee, Arnob
AU - Kobos, Rachel
AU - Usmani, Saad Z.
N1 - Funding Information: The authors acknowledge the patients and investigators who participated in this study, in addition to the staff members at the study sites, the Data Review and Safety Monitoring Committees, Alliance Foundation Trials (AFT; https://acknowledgments.alliancefound.org ), and the Janssen Team. This work was funded by Janssen Oncology. The MajesTEC-1 study was sponsored by Janssen Oncology and designed in partnership with AFT. Editorial and medical writing support were provided by Carolyn Farnsworth, Katie Yoest, PhD, and Katie Veleta, PhD, of MedThink SciCom and were funded by Janssen Global Services, LLC. Financial & competing interests disclosure Funding Information: The authors' full disclosure information can be found in the original research article. Writing support for this summary was provided under the direction of the author(s) by Katie Yoest, PhD, and Katie Veleta, PhD, of MedThink SciCom and was funded by Janssen Research and Development. Open access Publisher Copyright: © 2023 The Authors.
PY - 2023/4/1
Y1 - 2023/4/1
N2 - What is this summary about? This is a summary of a phase 1-2 clinical trial called MajesTEC-1. This trial tested the cancer drug teclistamab in people with relapsed or refractory multiple myeloma, a cancer that forms in a certain type of white blood cells known as plasma cells. Most participants who took part in the study had at least 3 prior treatments for multiple myeloma before their cancer came back. How was the study in this summary conducted? A total of 165 participants from 9 countries were included in this study. All participants were given teclistamab once per week and monitored for side effects. Once participants started taking teclistamab, they were checked regularly to monitor if their cancer had no change, improved (responded to treatment), or worsened or spread (known as disease progression). What were the results of the study? After approximately 14.1 months of follow-up (from 2020 to 2021), 63% of participants who were given teclistamab had a decrease in myeloma burden, meaning that they responded to treatment with teclistamab. Participants who responded to teclistamab lived without their myeloma coming back for approximately 18.4 months. The most common side effects were infections, cytokine release syndrome, abnormally low white and red blood cell counts (neutropenia, lymphopenia, and anemia), and low platelet cell counts (thrombocytopenia). Approximately 65% of participants experienced serious side effects. What do the results of this study mean? Overall, more than half of the participants (63%) in the MajesTEC-1 study responded to treatment with teclistamab despite previous myeloma treatment failures. Clinical Trial Registration: NCT03145181, NCT04557098 (ClinicalTrials.gov)
AB - What is this summary about? This is a summary of a phase 1-2 clinical trial called MajesTEC-1. This trial tested the cancer drug teclistamab in people with relapsed or refractory multiple myeloma, a cancer that forms in a certain type of white blood cells known as plasma cells. Most participants who took part in the study had at least 3 prior treatments for multiple myeloma before their cancer came back. How was the study in this summary conducted? A total of 165 participants from 9 countries were included in this study. All participants were given teclistamab once per week and monitored for side effects. Once participants started taking teclistamab, they were checked regularly to monitor if their cancer had no change, improved (responded to treatment), or worsened or spread (known as disease progression). What were the results of the study? After approximately 14.1 months of follow-up (from 2020 to 2021), 63% of participants who were given teclistamab had a decrease in myeloma burden, meaning that they responded to treatment with teclistamab. Participants who responded to teclistamab lived without their myeloma coming back for approximately 18.4 months. The most common side effects were infections, cytokine release syndrome, abnormally low white and red blood cell counts (neutropenia, lymphopenia, and anemia), and low platelet cell counts (thrombocytopenia). Approximately 65% of participants experienced serious side effects. What do the results of this study mean? Overall, more than half of the participants (63%) in the MajesTEC-1 study responded to treatment with teclistamab despite previous myeloma treatment failures. Clinical Trial Registration: NCT03145181, NCT04557098 (ClinicalTrials.gov)
KW - BCMA
KW - CD3
KW - bispecific antibody
KW - clinical trial
KW - immunotherapy
KW - lay summary
KW - multiple myeloma
KW - plain language summary
KW - relapsed/refractory multiple myeloma
KW - teclistamab
UR - http://www.scopus.com/inward/record.url?scp=85162194822&partnerID=8YFLogxK
U2 - https://doi.org/10.2217/fon-2023-0171
DO - https://doi.org/10.2217/fon-2023-0171
M3 - Review article
C2 - 37132225
SN - 1479-6694
VL - 19
SP - 811
EP - 818
JO - Future oncology (London, England)
JF - Future oncology (London, England)
IS - 12
ER -